DE60310975D1 - Verwendung von epothilone zur behandlung hyperparathyreoidismus - Google Patents

Verwendung von epothilone zur behandlung hyperparathyreoidismus

Info

Publication number
DE60310975D1
DE60310975D1 DE60310975T DE60310975T DE60310975D1 DE 60310975 D1 DE60310975 D1 DE 60310975D1 DE 60310975 T DE60310975 T DE 60310975T DE 60310975 T DE60310975 T DE 60310975T DE 60310975 D1 DE60310975 D1 DE 60310975D1
Authority
DE
Germany
Prior art keywords
epothilone
hyreoidism
hyperparate
treatment
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60310975T
Other languages
English (en)
Other versions
DE60310975T2 (de
Inventor
A Woltering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University and Agricultural and Mechanical College
Original Assignee
Louisiana State University and Agricultural and Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University and Agricultural and Mechanical College filed Critical Louisiana State University and Agricultural and Mechanical College
Publication of DE60310975D1 publication Critical patent/DE60310975D1/de
Application granted granted Critical
Publication of DE60310975T2 publication Critical patent/DE60310975T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60310975T 2002-10-15 2003-10-13 Verwendung von epothilone zur behandlung hyperparathyreoidismus Expired - Lifetime DE60310975T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
US418592P 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (en) 2002-10-15 2003-10-13 Use of epothilone derivatives for the treatment of hyperparathyroidism

Publications (2)

Publication Number Publication Date
DE60310975D1 true DE60310975D1 (de) 2007-02-15
DE60310975T2 DE60310975T2 (de) 2007-07-12

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60310975T Expired - Lifetime DE60310975T2 (de) 2002-10-15 2003-10-13 Verwendung von epothilone zur behandlung hyperparathyreoidismus

Country Status (16)

Country Link
US (2) US20060142354A1 (de)
EP (1) EP1553938B1 (de)
JP (1) JP4672368B2 (de)
CN (1) CN1297269C (de)
AT (1) ATE350034T1 (de)
AU (1) AU2003267751A1 (de)
BR (1) BR0315293A (de)
CA (1) CA2501717C (de)
CY (1) CY1106385T1 (de)
DE (1) DE60310975T2 (de)
DK (1) DK1553938T3 (de)
ES (1) ES2279139T3 (de)
HK (1) HK1080768A1 (de)
PT (1) PT1553938E (de)
SI (1) SI1553938T1 (de)
WO (1) WO2004035050A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1506203T3 (da) 2002-08-23 2007-05-14 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1155689T3 (da) * 1993-07-19 2006-11-20 Angiotech Pharm Inc Antiangiogene stents og fremgangsmåder til fremstilling heraf
BR9713363B1 (pt) * 1996-11-18 2011-02-08 processo para preparação de epotilona d.
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
TW457095B (en) * 1998-02-05 2001-10-01 Novartis Ag Pharmaceutical formulations comprising epothilones and lyophilised compositions comprising epothilones
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
CN1703217A (zh) 2005-11-30
WO2004035050A1 (en) 2004-04-29
EP1553938A1 (de) 2005-07-20
US20110152329A1 (en) 2011-06-23
BR0315293A (pt) 2005-08-30
CA2501717A1 (en) 2004-04-29
JP2006504751A (ja) 2006-02-09
DK1553938T3 (da) 2007-03-26
HK1080768A1 (en) 2006-05-04
DE60310975T2 (de) 2007-07-12
CA2501717C (en) 2012-09-18
SI1553938T1 (sl) 2007-06-30
AU2003267751A1 (en) 2004-05-04
CY1106385T1 (el) 2011-10-12
ES2279139T3 (es) 2007-08-16
PT1553938E (pt) 2007-03-30
EP1553938B1 (de) 2007-01-03
US20060142354A1 (en) 2006-06-29
ATE350034T1 (de) 2007-01-15
CN1297269C (zh) 2007-01-31
JP4672368B2 (ja) 2011-04-20

Similar Documents

Publication Publication Date Title
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
DE50310516D1 (de) Fredericamycin-derivate
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
DE60232173D1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DE60219680D1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
ATE369849T1 (de) Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
DE60302495D1 (de) Landwirtschaftliche Maschine zur Behandlung von Erntegut
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN